- Home
- KRNY vs NGNE Comparison
KRNY vs NGNE Comparison
Compare KRNY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNY
- NGNE
- Stock Information
- Founded
- KRNY 1884
- NGNE 2003
- Country
- KRNY United States
- NGNE United States
- Employees
- KRNY N/A
- NGNE N/A
- Industry
- KRNY Savings Institutions
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- KRNY Finance
- NGNE Health Care
- Exchange
- KRNY Nasdaq
- NGNE Nasdaq
- Market Cap
- KRNY 416.3M
- NGNE 426.6M
- IPO Year
- KRNY 2005
- NGNE N/A
- Fundamental
- Price
- KRNY $6.45
- NGNE $25.79
- Analyst Decision
- KRNY Buy
- NGNE Strong Buy
- Analyst Count
- KRNY 2
- NGNE 8
- Target Price
- KRNY $7.75
- NGNE $44.75
- AVG Volume (30 Days)
- KRNY 398.0K
- NGNE 252.5K
- Earning Date
- KRNY 10-23-2025
- NGNE 11-18-2025
- Dividend Yield
- KRNY 6.92%
- NGNE N/A
- EPS Growth
- KRNY N/A
- NGNE N/A
- EPS
- KRNY 0.47
- NGNE N/A
- Revenue
- KRNY $158,298,000.00
- NGNE N/A
- Revenue This Year
- KRNY $14.22
- NGNE N/A
- Revenue Next Year
- KRNY N/A
- NGNE N/A
- P/E Ratio
- KRNY $13.74
- NGNE N/A
- Revenue Growth
- KRNY 23.27
- NGNE N/A
- 52 Week Low
- KRNY $5.45
- NGNE $6.88
- 52 Week High
- KRNY $8.59
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- KRNY 45.92
- NGNE 43.47
- Support Level
- KRNY $6.26
- NGNE $27.28
- Resistance Level
- KRNY $6.49
- NGNE $32.99
- Average True Range (ATR)
- KRNY 0.14
- NGNE 3.16
- MACD
- KRNY -0.02
- NGNE -0.95
- Stochastic Oscillator
- KRNY 35.19
- NGNE 0.36
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.